A Study of TAK-227 in Healthy Adults
Study Details
Study Description
Brief Summary
The main aim of this study is to test the effects of food consumption with sponsor compound TAK-227 in healthy participants. The study will also measure side effects, and to check how much TAK-227 stays in the blood over time to work out the best dose.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
The drug being tested in this study is called TAK-227. This study will assess the effect of food on single-dose of TAK-227 in healthy participants.
The study will enroll approximately 24 participants. A single dose of 50 milligram (mg) TAK-227 will be administered orally under one of 3 different feeding conditions.
-
Fasting (Treatment A),
-
Fed following a high-fat or high-calorie meal prior to dosing (Treatment B), and
-
Fed following a high-fat or high-calorie meal after dosing (Treatment C)
Participants will be randomly assigned to 1 of the 6 treatments sequences based on the 3 feeding conditions.
-
Sequence 1: (Treatment A + Treatment B + Treatment C)
-
Sequence 2: (Treatment B + Treatment C + Treatment A)
-
Sequence 3: (Treatment C + Treatment A + Treatment B)
-
Sequence 4: (Treatment A + Treatment C + Treatment B)
-
Sequence 5: (Treatment B + Treatment A + Treatment C)
-
Sequence 6: (Treatment C + Treatment B + Treatment A)
All participants will receive all 6 treatment regimens. This is a single-center trial. Participants will be followed up for up to 7 days after the last dose of study drug for a follow-up assessment. The overall time to participate in this study is approximately 40 days including screening period and follow-up period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Sequence 1: (Treatment A + Treatment B + Treatment C) TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing. |
Drug: TAK-227
TAK-227 capsules.
|
| Experimental: Sequence 2: (Treatment B + Treatment C + Treatment A) TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A . There will be a washout period of at least 4 days between each dosing. |
Drug: TAK-227
TAK-227 capsules.
|
| Experimental: Sequence 3: (Treatment C + Treatment A + Treatment B) TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing. |
Drug: TAK-227
TAK-227 capsules.
|
| Experimental: Sequence 4: (Treatment A + Treatment C + Treatment B) TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing. |
Drug: TAK-227
TAK-227 capsules.
|
| Experimental: Sequence 5: (Treatment B + Treatment A + Treatment C) TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing. |
Drug: TAK-227
TAK-227 capsules.
|
| Experimental: Sequence 6: (Treatment C + Treatment B + Treatment A) TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A. There will be a washout period of at least 4 days between each dosing. |
Drug: TAK-227
TAK-227 capsules.
|
Outcome Measures
Primary Outcome Measures
- Cmax: Maximum Observed Plasma Concentration for TAK-227 [Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose]
- AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-227 [Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose]
- AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-227 [Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose]
Secondary Outcome Measures
- Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious TEAE [From start of study drug administration up to 7 days after the last dose (up to Day 16)]
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant who has signed the informed consent form (ICF) to participate in a study and it does not necessarily have to have a causal relationship with the treatment. An SAE is any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
- Number of Participants Based on Severity of TEAE [From start of study drug administration up to 7 days after the last dose (up to Day 16)]
Severity of a TEAE will be determined by following criteria: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
- Number of Participants Based on Causality of TEAE [From start of study drug administration up to 7 days after the last dose (up to Day 16)]
Causality of TEAE to the study medication will be assessed using the following categories: Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship is at least a reasonable possibility, that is, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, may also be responsible; Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments.
- Percentage of Participants With Clinically Significant Abnormal Change From Baseline to Post-Baseline in Vital Signs [Baseline to Day 10]
Vital signs will include body temperature (oral or tympanic measurement), respiratory rate, blood pressure [systolic blood pressure (SBP) and diastolic blood pressure (DBP)] resting more than 5 minutes, and pulse (beats per minute). Data for participants with clinically significant abnormal vital signs will be reported.
- Percentage of Participants With Clinically Significant Abnormal Change From Baseline to Post-Baseline in 12-Lead Electrocardiograms (ECG) [Baseline to Day 10]
ECGs will be performed with participants in a supine position. All ECG tracings will be reviewed by the Investigator or designee. Data for participants with clinically significant abnormal ECG values will be reported.
- Percentage of Participants With Clinically Significant Abnormal Change From Baseline to Post-Baseline in Laboratory Parameters [Baseline to Day 10]
The percentage of participants with any clinically significant abnormal laboratory values (hematology, serum chemistry, and urinalysis) will be collected throughout study. Clinically significant abnormal values for hematology will include hematocrit (percentage of hematocrit [%]), hemoglobin (grams per liter [g/L]), erythrocyte mean corpuscular volume (MCV)(femtoliter [fL]), erythrocytes (10^12/L), and leukocytes (10^9/L). Clinically significant abnormal values for serum chemistry will include alanine aminotransferase (units per liter [U/L]), aspartate aminotransferase (U/L), cholesterol (millimoles per liter [mmol/L]), gamma glutamyl transferase (U/L), glucose (mmol/L): < 2.8 mmol/L, potassium (mmol/L), sodium (mmol/L), and triglycerides (mmol/L). ULN is upper limit of normal and LLN is lower limit of normal.
- Percentage of Participants With Clinically Significant Change From Baseline to Post-Baseline in Physical Examination [Baseline to Day 10]
Physical examination will include the following body systems: (1) respiratory system; (2) cardiovascular system; (3) nervous system (4) dermatologic system; and (5) gastrointestinal system. A summarized data for the above body systems will be reported for participants with clinically significant findings.
Eligibility Criteria
Criteria
Inclusion Criteria
Participants must fulfill the following inclusion criteria to be eligible for participation in the study:
-
Body mass index (BMI) greater than or equal to (>=) 18 and less than or equal to (<=) 32.0 kilogram per square meter (kg/m^2) at screening visit.
-
Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing based on participant self-reporting.
Exclusion Criteria:
Participants must not be enrolled in the study if they meet any of the following criteria:
-
Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
-
Drink alcohol in excess of 21 units per week for males or 14 units per week for females, with one unit equal to (=) 150 milliliter (mL) of wine or 360 mL of beer or 45 mL of 45 percent (%) alcohol.
-
Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
-
Unable to refrain from or anticipates the use of:
-
Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study. Medication listed as part of acceptable birth control methods will be allowed. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first study drug administration. Hormone replacement therapy will also be allowed.
-
Any drugs known to be significant inducers or inhibitors of Cytochrome P450 (CYP)3A4 enzymes and/or P-glycoprotein (gp), including St. John's Wort, within 28 days prior to the first dosing and throughout the study. Appropriate sources (example, Flockhart Table TM) will be consulted to confirm lack of pharmacokinetic (PK)/pharmacodynamics interaction with study drug.
-
Chronic use of non-steroidal anti-inflammatory (define as more that 7 days of use) within 2 weeks prior to screening and throughout the study.
-
Donation of blood or significant blood loss within 56 days prior to the first dosing.
-
Plasma donation within 7 days prior to the first dosing.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Celerion, Inc. | Tempe | Arizona | United States | 85282 |
Sponsors and Collaborators
- Takeda
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- TAK-227-1001